인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition associated with high rates of morbidity and mortality, mainly due to post-hemorrhagic complications such as cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI). Recent evidence implicates platelet activation and inflammatory mediators in the cascade of secondary injury following aSAH. Monitoring and timely treatment of post-SAH complications is critical to improve clinical outcomes. Current methods of radiological diagnostic for monitoring are laborious and bound to multiple risks, including radiation exposure. Point-of-care blood biomarkers early after SAH are urgently needed to timely detect and treat post-SAH complications. This prospectively designed cohort study aimed to search for novel predictive biomarkers for vasospasm and clinical outcome with overarching goal to improve treatment decision during intensive care treatment. In this prospective study conducted from 2020 to 2022, 63 aSAH patients (16 male and 47 female) were enrolled. Blood samples were collected to measure platelet factor 4 (PF4) and stromal cell derived factor (SDF) levels. To detect vasospasm, computed tomography (CT) perfusions at day 0, 4, 7 and 11 after the SAH was performed and mean transient time (MTT) was quantified as a measure of cerebral perfusion. Clinical outcome was analysed using modified rankin scale (mRS). Clinical and radiological data was recorded prospectively. The association between PF4 levels and CVS was assessed using receiver operating characteristic (ROC) curve analysis and logistic regression, while linear regression analyses were performed to examine the correlations of PF4 with mean transit times (MTT) and of SDF with the day of death among non-survivors. Logistic regression revealed that each 1 ng/mL increase in PF4 was associated with a 38% increase in the odds of developing CVS (OR = 1.38; 95% CI: 1.07-1.79; p = 0.01). Moreover, elevated PF4 levels were significantly correlated with longer MTT (β = 0.107 per ng/mL; 95% CI: 0.02-0.19; p = 0.02), suggesting impaired cerebral perfusion. Additionally, among non-surviving patients, higher SDF levels were significantly associated with a later occurrence of death (β = 0.01 per pg/mL; 95% CI: 0.001-0.019; p = 0.03). The findings indicate that PF4 and SDF are promising biomarkers in aSAH. Elevated PF4 levels are associated with an increased risk of CVS and impaired cerebral perfusion, while higher SDF levels correlate with mortality. These biomarkers may offer valuable insights for early risk stratification and pave the way for targeted therapeutic interventions in patients with aSAH.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
